Boule Diagnostics AB (BOUL) - Total Assets
Based on the latest financial reports, Boule Diagnostics AB (BOUL) holds total assets worth Skr465.40 Million SEK (≈ $50.08 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Boule Diagnostics AB - Total Assets Trend (2005–2024)
This chart illustrates how Boule Diagnostics AB's total assets have evolved over time, based on quarterly financial data. Also see Boule Diagnostics AB (BOUL) total market value for the company's overall valuation and market capitalisation.
Boule Diagnostics AB - Asset Composition Analysis
Current Asset Composition (December 2024)
Boule Diagnostics AB's total assets of Skr465.40 Million consist of 43.2% current assets and 56.8% non-current assets. Review Boule Diagnostics AB (BOUL) total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr22.65 Million | 3.9% |
| Accounts Receivable | Skr167.40 Million | 28.4% |
| Inventory | Skr59.10 Million | 10.0% |
| Property, Plant & Equipment | Skr39.48 Million | 6.7% |
| Intangible Assets | Skr99.70 Million | 16.9% |
| Goodwill | Skr91.92 Million | 15.6% |
Asset Composition Trend (2005–2024)
This chart illustrates how Boule Diagnostics AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Boule Diagnostics AB share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Boule Diagnostics AB's current assets represent 43.2% of total assets in 2024, an increase from 0.0% in 2005.
- Cash Position: Cash and equivalents constituted 3.9% of total assets in 2024, down from 14.0% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 31.0% of total assets, a decrease from 94.0% in 2005.
- Asset Diversification: The largest asset category is accounts receivable at 28.4% of total assets.
Boule Diagnostics AB Competitors by Total Assets
Key competitors of Boule Diagnostics AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Medtronic plc
SA:MDTC34
|
Brazil | R$93.03 Billion |
|
Demant A/S
CO:DEMANT
|
Denmark | Dkr39.07 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.89 Billion |
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.20 Billion |
|
Sinocare Inc
SHE:300298
|
China | CN¥6.25 Billion |
|
Emvision Medical Devices Ltd
AU:EMV
|
Australia | AU$24.94 Million |
|
Theradiag SA
PA:ALTHE
|
France | €11.55 Million |
|
Biosynex
PA:ALBIO
|
France | €149.44 Million |
Boule Diagnostics AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.02 | 1.23 | 1.42 |
| Quick Ratio | 0.74 | 0.93 | 1.09 |
| Cash Ratio | 0.10 | 0.00 | 0.00 |
| Working Capital | Skr5.40 Million | Skr53.30 Million | Skr69.90 Million |
Boule Diagnostics AB - Advanced Valuation Insights
This section examines the relationship between Boule Diagnostics AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.36 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | -21.8% |
| Total Assets | Skr590.20 Million |
| Market Capitalization | $10.66 Million USD |
Valuation Analysis
Below Book Valuation: The market values Boule Diagnostics AB's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Boule Diagnostics AB's assets decreased by 21.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Boule Diagnostics AB (2005–2024)
The table below shows the annual total assets of Boule Diagnostics AB from 2005 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr590.20 Million ≈ $63.51 Million |
-21.84% |
| 2023-12-31 | Skr755.11 Million ≈ $81.26 Million |
-0.64% |
| 2022-12-31 | Skr759.96 Million ≈ $81.78 Million |
+32.85% |
| 2021-12-31 | Skr572.03 Million ≈ $61.56 Million |
+19.24% |
| 2020-12-31 | Skr479.71 Million ≈ $51.62 Million |
-18.26% |
| 2019-12-31 | Skr586.87 Million ≈ $63.16 Million |
+17.17% |
| 2018-12-31 | Skr500.85 Million ≈ $53.90 Million |
+20.25% |
| 2017-12-31 | Skr416.49 Million ≈ $44.82 Million |
+14.32% |
| 2016-12-31 | Skr364.33 Million ≈ $39.21 Million |
+15.48% |
| 2015-12-31 | Skr315.48 Million ≈ $33.95 Million |
+12.69% |
| 2014-12-31 | Skr279.95 Million ≈ $30.13 Million |
+26.84% |
| 2013-12-31 | Skr220.72 Million ≈ $23.75 Million |
-19.81% |
| 2012-12-31 | Skr275.23 Million ≈ $29.62 Million |
+1.24% |
| 2011-12-31 | Skr271.85 Million ≈ $29.26 Million |
+31.89% |
| 2010-12-31 | Skr206.11 Million ≈ $22.18 Million |
+37.99% |
| 2009-12-31 | Skr149.37 Million ≈ $16.07 Million |
-11.28% |
| 2008-12-31 | Skr168.36 Million ≈ $18.12 Million |
-1.90% |
| 2007-12-31 | Skr171.62 Million ≈ $18.47 Million |
+3.75% |
| 2006-12-31 | Skr165.42 Million ≈ $17.80 Million |
-5.28% |
| 2005-12-31 | Skr174.63 Million ≈ $18.79 Million |
-- |
About Boule Diagnostics AB
Boule Diagnostics AB (publ) develops, manufactures, and markets instruments and consumable products for blood diagnostics in the United States of America, Asia, Eastern Europe, Latin America, Western Europe, Africa, and the Middle East. The company provides hematology analyzers, reagents, controls, and calibrators, under the Swelab, Medonic, and Quintus brands; and veterinary hematology and clini… Read more